PH12017501016B1 - Triazolopyrimidine compounds and uses thereof - Google Patents

Triazolopyrimidine compounds and uses thereof

Info

Publication number
PH12017501016B1
PH12017501016B1 PH12017501016A PH12017501016A PH12017501016B1 PH 12017501016 B1 PH12017501016 B1 PH 12017501016B1 PH 12017501016 A PH12017501016 A PH 12017501016A PH 12017501016 A PH12017501016 A PH 12017501016A PH 12017501016 B1 PH12017501016 B1 PH 12017501016B1
Authority
PH
Philippines
Prior art keywords
triazolopyrimidine compounds
triazolopyrimidine
compounds
prc2
disorder
Prior art date
Application number
PH12017501016A
Other languages
English (en)
Other versions
PH12017501016A1 (en
Inventor
Ho Man Chan
Xiang-Ju Justin Gu
Ying Huang
Ling Li
Yuan Mi
Wei Qi
Martin Sendzik
Long Wang
Zhengtian Yu
Hailong Zhang
Ji Yue Zhang (Jeff)
Man Zhang
Qiong Zhang
Kehao Zhao
Yongfeng Sun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12017501016A1 publication Critical patent/PH12017501016A1/en
Publication of PH12017501016B1 publication Critical patent/PH12017501016B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12017501016A 2014-12-23 2017-06-01 Triazolopyrimidine compounds and uses thereof PH12017501016B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (2)

Publication Number Publication Date
PH12017501016A1 PH12017501016A1 (en) 2017-12-11
PH12017501016B1 true PH12017501016B1 (en) 2017-12-11

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501016A PH12017501016B1 (en) 2014-12-23 2017-06-01 Triazolopyrimidine compounds and uses thereof

Country Status (40)

Country Link
US (5) US10220036B2 (enExample)
EP (1) EP3237418B1 (enExample)
JP (1) JP6736559B2 (enExample)
KR (1) KR102534028B1 (enExample)
CN (1) CN107108637B (enExample)
AU (1) AU2015370524B2 (enExample)
BR (1) BR112017010354B8 (enExample)
CA (1) CA2969090C (enExample)
CL (1) CL2017001572A1 (enExample)
CO (1) CO2017005992A2 (enExample)
CR (1) CR20170285A (enExample)
CY (1) CY1121901T1 (enExample)
DK (1) DK3237418T3 (enExample)
DO (1) DOP2017000149A (enExample)
EA (1) EA032416B1 (enExample)
EC (1) ECSP17047153A (enExample)
ES (1) ES2722048T3 (enExample)
GT (1) GT201700146A (enExample)
HR (1) HRP20190805T1 (enExample)
HU (1) HUE043060T2 (enExample)
IL (1) IL252135B (enExample)
JO (1) JO3489B1 (enExample)
LT (1) LT3237418T (enExample)
ME (1) ME03385B (enExample)
MX (1) MX375970B (enExample)
MY (1) MY186837A (enExample)
NZ (1) NZ731664A (enExample)
PE (1) PE20171307A1 (enExample)
PH (1) PH12017501016B1 (enExample)
PL (1) PL3237418T3 (enExample)
PT (1) PT3237418T (enExample)
RS (1) RS58679B1 (enExample)
SG (1) SG11201703880VA (enExample)
SI (1) SI3237418T1 (enExample)
SV (1) SV2017005472A (enExample)
TN (1) TN2017000204A1 (enExample)
TW (1) TWI694076B (enExample)
UA (1) UA120945C2 (enExample)
UY (1) UY36462A (enExample)
WO (1) WO2016103155A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171307A1 (es) * 2014-12-23 2017-09-05 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
MX388824B (es) * 2016-06-20 2025-03-20 Novartis Ag Formas cristalinas de compuesto de triazolopirimidina.
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
ES2798424T3 (es) * 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
CR20190063A (es) 2016-07-12 2019-05-27 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
CN110431134A (zh) 2017-01-23 2019-11-08 锐新医药公司 作为变构shp2抑制剂的吡啶化合物
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
BR112019017108A2 (pt) * 2017-03-16 2020-04-07 Jiangsu Hengrui Medicine Co derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
WO2019145176A1 (en) * 2018-01-23 2019-08-01 Basf Se Halogenation of pyridine derivatives
HUE069170T2 (hu) 2018-01-31 2025-02-28 Mirati Therapeutics Inc PRC2-inhibitorok
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
AU2019386036A1 (en) * 2018-11-30 2021-05-27 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CA3133751A1 (en) * 2019-03-15 2020-09-24 Fulcrum Therapeutics, Inc. Macrocyclic azolopyridine derivatives as eed and prc2 modulators
EP3950064A4 (en) * 2019-04-03 2023-01-04 Tera Stone Co., Ltd THYMINE NUCLEOBASE BASED TRIAZOLOPYRIMIDINES AND PROCESS FOR THEIR PRODUCTION
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
KR20220027933A (ko) * 2019-06-05 2022-03-08 미라티 테라퓨틱스, 인크. 암을 치료하기 위한 prc2 억제제로서의 이미다조[1,2-c]피리미딘 유도체
TW202112379A (zh) * 2019-06-05 2021-04-01 美商亞瑟尼克斯公司 治療及／或預防乾癬之方法
BR112022000713A2 (pt) 2019-07-16 2022-03-22 Univ Michigan Regents Imidazopirimidinas como inibidores de eed e o uso das mesmas
PH12022550441A1 (en) 2019-08-22 2022-12-19 Blueray Therapeutics Shanghai Co Ltd Azaheteroaryl compound and application thereof
IL291499B2 (en) * 2019-09-26 2025-08-01 Novartis Ag Aza-quinoline compounds and uses thereof
JP7481689B2 (ja) * 2019-11-01 2024-05-13 上海科技大学 Ｅｅｄ阻害剤、その製造方法およびその使用
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
WO2021228034A1 (en) * 2020-05-11 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
AU2021281123A1 (en) 2020-05-28 2023-02-09 Novartis Ag Dosing regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-C]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating PRC2-mediated diseases or disorders
CN114907385A (zh) * 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
CN101939006B (zh) 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PH12012502194A1 (en) * 2010-05-07 2014-09-05 Glaxosmithkline Llc Indoles
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
KR20140082742A (ko) 2011-09-30 2014-07-02 글락소스미스클라인 엘엘씨 암을 치료하는 방법
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
CA2900764A1 (en) 2013-02-08 2014-08-14 Stemcentrx, Inc. Novel multispecific constructs
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
US9776996B2 (en) * 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015123365A1 (en) 2014-02-11 2015-08-20 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN107108385B (zh) 2014-11-14 2021-09-24 巴斯夫欧洲公司 作为硝化抑制剂的苄基炔丙基醚
ES2668688T3 (es) 2014-12-16 2018-05-21 Omya International Ag Carbonato de calcio para protección vegetal
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PE20171307A1 (es) * 2014-12-23 2017-09-05 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
SG11201703880VA (en) 2017-07-28
US11207325B2 (en) 2021-12-28
MX2017008529A (es) 2017-10-25
AU2015370524A1 (en) 2017-06-01
PH12017501016A1 (en) 2017-12-11
KR102534028B1 (ko) 2023-05-19
JP2018500342A (ja) 2018-01-11
US20160176882A1 (en) 2016-06-23
BR112017010354B8 (pt) 2022-10-18
EP3237418A1 (en) 2017-11-01
US20230033320A1 (en) 2023-02-02
AU2015370524B2 (en) 2018-11-01
PT3237418T (pt) 2019-05-23
US20170348312A1 (en) 2017-12-07
HUE043060T2 (hu) 2019-07-29
SI3237418T1 (sl) 2019-06-28
ME03385B (me) 2020-01-20
SV2017005472A (es) 2018-06-12
BR112017010354A2 (pt) 2017-12-26
CO2017005992A2 (es) 2017-10-20
IL252135B (en) 2020-06-30
PL3237418T3 (pl) 2019-07-31
JO3489B1 (ar) 2020-07-05
EA032416B1 (ru) 2019-05-31
TW201629065A (zh) 2016-08-16
EP3237418B1 (en) 2019-01-30
CA2969090C (en) 2023-05-02
TN2017000204A1 (en) 2018-10-19
HRP20190805T1 (hr) 2019-06-28
US20200323859A1 (en) 2020-10-15
KR20170095882A (ko) 2017-08-23
MY186837A (en) 2021-08-25
CY1121901T1 (el) 2020-10-14
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
JP6736559B2 (ja) 2020-08-05
BR112017010354B1 (pt) 2022-09-20
ECSP17047153A (es) 2019-02-28
EA201791420A1 (ru) 2017-10-31
LT3237418T (lt) 2019-05-10
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
DK3237418T3 (da) 2019-05-13
CA2969090A1 (en) 2016-06-30
RS58679B1 (sr) 2019-06-28
WO2016103155A1 (en) 2016-06-30
ES2722048T3 (es) 2019-08-07
CN107108637A (zh) 2017-08-29
US9580437B2 (en) 2017-02-28
CL2017001572A1 (es) 2018-01-12
MX375970B (es) 2025-03-06
UY36462A (es) 2016-07-29
IL252135A0 (en) 2017-07-31
UA120945C2 (uk) 2020-03-10
US11931363B2 (en) 2024-03-19
CR20170285A (es) 2017-08-21
NZ731664A (en) 2024-02-23
DOP2017000149A (es) 2017-07-15
GT201700146A (es) 2019-06-12
CN107108637B (zh) 2019-10-29

Similar Documents

Publication Publication Date Title
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
MX2021014128A (es) Polimorfos de selinexor.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12016500225B1 (en) Novel quinoline-substituted compound
TW201613872A (en) IRAK4 inhibiting agents
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
MY197698A (en) Oxysterols and methods of use thereof
PH12017500095A1 (en) Imidazopyridazine compounds
JO3318B1 (ar) مثبطات bace
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2016004967A (es) Tratamiento para cancer pancreatico.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IN2014MU00195A (enExample)
PH12017500492A1 (en) Crystalline bace inhibitors
PH12015502703A1 (en) Pharmaceutical compositions
IN2014MU00194A (enExample)
IN2014MU01196A (enExample)
IN2014MU00858A (enExample)